Subclinical atherosclerosis in PsA
| Study | Design | Findings |
|---|---|---|
| Gonzalez-Juanatey22 | Case–control study; 50 patients and 50 matched healthy controls | Postocclusion FMD was significantly impaired in patients; no correlation with inflammatory markers |
| Gonzalez-Juanatey23 | Case–control study; 59 patients and 59 matched healthy controls | Mean IMT was 0.06 mm increased in patients (p=0.031); no correlation with inflammatory markers and DAS28 |
| Kimhi24 | Case–control study; 47 patients and 100 controls; patients with cardiovascular disease were not excluded | After adjustment for traditional cardiovascular risk factors mean IMT was 0.04 mm increased in PsA patients (p=0.04) |
| Eder21 | Case–control study; 40 patients and 40 matched controls | Mean IMT was 0.16 mm increased in PsA patients (p=0.03); carotid plaque index was higher among patients (p=0.03) |
| Tam25 | Case–control study; 82 patients and 82 matched healthy controls | Mean IMT was 0.11 mm increased in PsA patients (p<0.001); prevalence of carotid plaques was significantly higher in patients (p<0.001) |
| Di Minno20 | Case–control study; 224 patients and 305 matched healthy controls | PsA patients without cardiovascular risk factors had a 0.16 mm higher IMT than controls (p=0.025) |
DAS28, disease activity score in 28 joints; FMD, flow-mediated vasodilatation; IMT, intima-media thickness; PsA, psoriatic arthritis.